Oncosyne develops in vitro diagnostic tools that utilize patient-derived micro-tumors to evaluate individual responses to various cancer therapies. This technology addresses the issue of ineffective treatments and harmful side effects in oncology by providing precise drug efficacy predictions, enabling tailored therapeutic decisions for improved patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Oncological therapy often involves under- and over-treatment due to a lack of diagnostic tools that accurately predict individual patient responses to various drugs. Many patients receive chemotherapy without clinical benefit, suffering harmful side effects and contributing to healthcare waste.
Solution
Oncosyne addresses this issue with its iCAN tumoroid platform, which cultivates patient-derived microtumors to screen drug efficacy. This clinical-grade drug screening platform enables personalized medicine by identifying which cancer drugs are most likely to be effective for individual patients. The iCAN platform supports both iCAN R&D, a drug development platform used in all phases of pharmaceutical development, and iCAN IVD, an in vitro diagnostic test that personalizes optimal treatment for each patient. The company's diagnostic report identifies both efficacious and inefficacious cancer drugs, serving as a therapeutic decision tool for pharmaceutical companies, medical laboratories, and hospitals.
Target Audience
Oncosyne's primary customers include pharmaceutical companies seeking to accelerate drug discovery, as well as medical laboratories and hospitals aiming to personalize cancer treatment decisions.
Features
- Predictive tumoroid drug screening tools for colorectal and pancreatic cancer
- iCAN R&D platform for drug development, covering discovery to patient stratification
- iCAN IVD platform for personalized treatment selection
- Cultivation of patient's own living cancer cells for drug efficacy testing
- Identification of both efficacious and inefficacious drugs and drug combinations
- Clinical-grade drug screening for improved therapeutic precision